| Mechanisms of smooth muscle contraction A Horowitz, CB Menice, R Laporte, KG Morgan Physiological reviews 76 (4), 967-1003, 1996 | 976 | 1996 |
| A role for MAP kinase in differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation C Dessy, I Kim, CL Sougnez, R Laporte, KG Morgan American Journal of Physiology-Cell Physiology 275 (4), C1081-C1086, 1998 | 199 | 1998 |
| Pharmacological modulation of sarcoplasmic reticulum function in smooth muscle R Laporte, A Hui, I Laher Pharmacological reviews 56 (4), 439-513, 2004 | 128 | 2004 |
| A selective V1A receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock X He, F Su, FS Taccone, R Laporte, AL Kjølbye, J Zhang, K Xie, ... Critical care medicine 44 (1), 23-31, 2016 | 78 | 2016 |
| The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis MO Maybauer, DM Maybauer, P Enkhbaatar, R Laporte, H Wisniewska, ... Critical care medicine 42 (7), e525-e533, 2014 | 72 | 2014 |
| Isozyme-specific inhibitors of protein kinase C translocation: effects on contractility of single permeabilized vascular muscle cells of the ferret YH Lee, I Kim, R Laporte, MP Walsh, KG Morgan The Journal of Physiology 517 (Pt 3), 709, 1999 | 71 | 1999 |
| Angiotensin II amplifies arterial contractile response to norepinephrine without increasing Ca++ influx: role of protein kinase C. D Henrion, I Laher, R Laporte, JA Bevan Journal of Pharmacology and Experimental Therapeutics 261 (3), 835-840, 1992 | 71 | 1992 |
| Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial F Simon, R Giudici, A Scheuerle, M Gröger, P Asfar, JA Vogt, U Wachter, ... Critical Care 13, 1-11, 2009 | 61 | 2009 |
| Further evidence from an elastic artery that angiotensin II amplifies noradrenaline-induced contraction through activation of protein kinase C D Henrion, I Laher, R Laporte, JA Bevan European journal of pharmacology 224 (1), 13-20, 1992 | 48 | 1992 |
| Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory … R Laporte, A Kohan, J Heitzmann, H Wiśniewska, J Toy, E La, H Tariga, ... Journal of Pharmacology and Experimental Therapeutics 337 (3), 786-796, 2011 | 45 | 2011 |
| New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists K Wisniewski, R Galyean, H Tariga, S Alagarsamy, G Croston, ... Journal of medicinal chemistry 54 (13), 4388-4398, 2011 | 44 | 2011 |
| Sarcoplasmic reticulum-sarcolemma interactions and vascular smooth muscle tone R Laporte, I Laher Journal of vascular research 34 (5), 325-343, 1997 | 41 | 1997 |
| New, potent, and selective peptidic oxytocin receptor agonists K Wiśniewski, S Alagarsamy, R Galyean, H Tariga, D Thompson, B Ly, ... Journal of Medicinal Chemistry 57 (12), 5306-5317, 2014 | 40 | 2014 |
| Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome DM Hargrove, S Alagarsamy, G Croston, R Laporte, S Qi, K Srinivasan, ... Journal of Pharmacology and Experimental Therapeutics 373 (2), 193-203, 2020 | 37 | 2020 |
| Phorbol ester-induced potentiation of myogenic tone is not associated with increases in Ca2+ influx, myoplasmic free Ca2+ concentration, or 20-kDa myosin light chain … R Laporte, JR Haeberle, I Laher Journal of molecular and cellular cardiology 26 (3), 297-302, 1994 | 31 | 1994 |
| Synthesis and pharmacological characterization of novel glucagon-like peptide-2 (GLP-2) analogues with low systemic clearance K Wiśniewski, J Sueiras-Diaz, G Jiang, R Galyean, M Lu, D Thompson, ... Journal of Medicinal Chemistry 59 (7), 3129-3139, 2016 | 29 | 2016 |
| Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor S Rehberg, P Enkhbaatar, J Rehberg, E La, N Ferdyan, S Qi, ... Critical care medicine 40 (6), 1957-1960, 2012 | 22 | 2012 |
| Use of v2 receptor antagonists in combination with vaso pressinergic agnosts PJ Riviere, S Alagarsamy, CD Schteingart, R Laporte US Patent App. 12/680,452, 2010 | 17 | 2010 |
| Nonpeptide oxytocin agonists DM Ashworth, AR Batt, AJ Baxter, P Broqua, RM Haigh, P Hudson, ... Drugs of the Future 31 (4), 2006 | 16 | 2006 |
| Effects of exercise on skeletal muscle and serum enzyme activities in pigs F Doizé, R Laporte, L DeRoth Veterinary Research Communications 13, 341-347, 1989 | 16 | 1989 |
Kathleen G. MorganBoston UniversityVerified email at bu.edu
